Supportive Measures in Treatment of Aluminum Phosphide Poisoning

Detection of Different Prognostic Factors and Their Relation With the Outcome Clinical Trial

Official title:

Supportive Measures in Treatment of Aluminum Phosphide Poisoning as a Trial to Reduce Mortality at Assiut University Hospital

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03879356
• Other study ID #: AluminumPhosphideAssiut
• Status: Completed
• Phase: Phase 4
• Start date: January 1, 2016
• Est. completion date: March 14, 2017

Study information

• Verified date: March 2019
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Aluminum phosphide poisoning (ALP) is a global public health problem, and self-poisoning accounts for one-third of the world's suicide rate. In fact, in some parts of developing countries, pesticide poisoning causes more deaths than infection. ALP is very common in our government and the prognosis of the cases is usually so bad. Toxicity by ALP is caused by the liberation of phosphine gas, which causes cell hypoxia due to inhibition of oxidative phosphorylation leading to circulatory failure.

Description:

Aluminum phosphide poisoning is a major problem, accounting for many Emergency Unit visits and hospitalization, the incidence of aluminum phosphide poisoning increasing in the last few years.

ALP is used as pesticides for many years to protect grains in stores and during its transportation. The availability of these tablets and their low cost make it an easy and common method of suicide in our country with the increasing incidence of social and financial problems that face the youth.

In management, the main objective is to provide effective oxygenation, ventilation, and circulation until phosphine is excreted. All patients of severe ALP poisoning require continuous invasive hemodynamic monitoring and early resuscitation with fluid and vasoactive agents. N- acetylcysteine as an antioxidant and cytoprotective agent reduces myocardial oxidative injury and increase survival time. Magnesium sulfate helps in scavenging free radicals through glutathione (GSH) recovery hence is effective as a parenteral antioxidant in this poisoning as well as has been tried for its general membrane stabilizing effect in cardiac cells .

Death after 24 hours occurs usually owing to shock, cardiac arrhythmia, metabolic acidosis, and acute respiratory distress syndrome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: March 14, 2017
• Est. primary completion date: June 30, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• All the cases with the primary diagnosis of Aluminum phosphide toxicity will be included in the study.

• Willing and able to comply with the study procedures and provide written informed consent to participate in the study.

Exclusion Criteria:

• Patients with a history of any chronic disease (renal and hepatic).

• Patients refuse to participate in the study.

• Aged less than 18 years

Related Conditions & MeSH terms

• Detection of Different Prognostic Factors and Their Relation With the Outcome
• Poisoning
• Using New Protocol to Prove the Role of N-acetyl Cysteine and Adequate Supportive Measures in Aluminum Phosphide Poisoning

Intervention

Drug:
• N-acetyl cysteine
effect of N-acetyl cysteine in Aluminum phosphide poisoning patients

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	mortality rate comparison	comparison of mortality rate using the New protocol and previous mortality rate from archive records	3 days
Primary	hospital stay	number of days the patient stayed at hospital	3 days